What Is Parenchymal Scarring? Causes and Effects

Parenchymal scarring is the replacement of an organ’s functional tissue with dense, fibrous scar tissue after injury or chronic inflammation. “Parenchyma” refers to the working cells of any organ, whether they are the tiny air sacs in your lungs, the filtering units in your kidneys, or the metabolic cells in your liver. When those cells are damaged and the body’s repair process overshoots or never fully resolves, collagen-rich scar tissue accumulates in their place, and the organ gradually loses its ability to do its job. The process can affect virtually any organ, and the consequences range from mild and stable to life-threatening, depending on where the scarring occurs and how far it has progressed.

How the Scarring Process Works

Every organ has a built-in repair system. When tissue is injured, specialized cells ramp up production of structural proteins to patch the wound, much like a construction crew filling a pothole. The key worker in this process is a cell called the myofibroblast, which is the primary collagen-producing cell during tissue repair. Myofibroblasts can arise from several sources, including the organ’s own resident cells and circulating cells that migrate in from the bloodstream.¹ In a healthy repair cycle, myofibroblasts do their job and then quiet down once the wound is closed. The trouble starts when they stay active. Persistent myofibroblast activation triggers pathological fibrosis, meaning collagen keeps accumulating long after the original injury has healed.²

A major chemical signal driving this process is a molecule called TGF-β (transforming growth factor-beta). TGF-β is sometimes described as a universal driver of fibrosis because it shows up in scarring across virtually every organ system. It pushes cells to produce more extracellular matrix, the scaffold of proteins and fibers that gives tissue its shape, and it also influences whether cells survive, die, or change identity.³ Because TGF-β is so central to the scarring cascade, it has become one of the main targets researchers are trying to block or dial down with new therapies.⁴

Parenchymal Scarring in the Lungs

Lung scarring is one of the most clinically significant forms of parenchymal fibrosis, partly because the lungs depend on soft, elastic tissue to expand and exchange gases. Scarring can result from infections, environmental exposures like asbestos or silica dust, certain medications, radiation therapy, and autoimmune conditions.⁵ When scar tissue builds up in the lung parenchyma, the tissue stiffens, compliance drops, and the surface area available for oxygen to pass into the blood shrinks.

Idiopathic pulmonary fibrosis, or IPF, is the most severe and well-studied form. In IPF, the lung parenchyma and its architecture are progressively destroyed, and gas exchange is compromised to the point of respiratory failure, with a typical survival of roughly three to five years after diagnosis.⁶ Not all lung scarring is this aggressive. Some patients develop limited scars from a past infection like tuberculosis or pneumonia and live for decades without significant breathing problems. The outcome depends heavily on whether the scarring is still progressing or has stabilized.

A comparison between IPF and another scarring lung condition, sarcoidosis, illustrates how different patterns of scarring produce different levels of impairment. At a similar degree of volume loss, patients with sarcoidosis tended to have relatively preserved gas exchange compared with IPF patients, whose oxygen transfer was more severely impaired.⁷ In other words, the location and pattern of scarring within the lung matter as much as its overall extent.

Things get more complicated when scarring and emphysema coexist in the same patient. In combined pulmonary fibrosis and emphysema, the two conditions partially offset each other’s effects on lung volumes but gang up on gas exchange, producing a severe drop in the lung’s ability to transfer oxygen into the blood.⁸

Scarring in the Kidneys

Renal parenchymal scarring most commonly develops after repeated or severe kidney infections, especially in children. The link between urinary tract infections, a condition called vesicoureteral reflux (where urine flows backward from the bladder toward the kidneys), and permanent kidney scars is well established. Higher grades of reflux and recurrent infections both raise the risk of scarring.⁹ Additional risk factors include delayed antibiotic treatment and dysfunctional voiding patterns.¹⁰

The most well-known long-term consequence of kidney scarring in children is high blood pressure. A study using ambulatory blood pressure monitoring found that roughly a third of children with renal parenchymal scarring had hypertension that was not detected by standard office measurements alone. Early detection of this “masked” hypertension matters because untreated high blood pressure can accelerate further kidney damage and increase the risk of cardiovascular problems later in life.¹¹

Scarring in the Liver

Liver fibrosis follows the same general playbook but with its own cast of cells. In the liver, the main collagen-producing cell when injury occurs is the hepatic stellate cell, which activates in response to damage and begins depositing extracellular matrix.¹² The most common causes are chronic viral hepatitis (especially hepatitis B and C) and fatty liver disease related to obesity or heavy alcohol use.

Liver fibrosis is essentially the precursor to cirrhosis. As collagen continues to accumulate, the liver’s normal architecture becomes distorted, blood flow through the organ is disrupted, and eventually the organ can no longer perform its metabolic and detoxification functions adequately.¹³ Early-stage fibrosis is often silent, producing no symptoms. By the time cirrhosis develops, the late stages are irreversible.¹⁴ This makes early detection and treatment of the underlying cause especially important in liver disease; catching fibrosis before it progresses to full cirrhosis can change the outcome entirely.

Scarring in the Heart

Cardiac fibrosis develops when heart muscle cells die and scar tissue fills the void. This often follows a heart attack, where a patch of muscle starved of blood flow is replaced by collagen. That replacement scar preserves the heart’s structural shape, but it cannot contract like muscle, so it weakens the heart’s pumping ability.¹⁵ Beyond heart attacks, cardiac fibrosis is driven by chronic conditions like high blood pressure, diabetes, and aging. The excessive collagen stiffens the heart wall, disrupts its electrical signaling, and contributes to heart failure and arrhythmias.¹⁶

Fibrosis in the heart does not have to follow an acute event. In long-standing high blood pressure, collagen gradually accumulates around the small blood vessels within the heart muscle and in the spaces between muscle fibers. This interstitial fibrosis disrupts both the mechanical and electrical behavior of the heart and is considered a structural basis for the progression from compensated hypertrophy to outright heart failure.¹⁷

Glial Scarring in the Brain

The brain does not scar the same way other organs do. Instead of collagen-producing fibroblasts, the brain relies on cells called astrocytes and microglia to wall off damaged areas after a stroke or traumatic injury. The barrier they build is called a glial scar. This scar is a critical part of the healing response: it compartmentalizes dead tissue and limits the spread of toxic molecules into healthy brain regions.¹⁸

Glial scar formation has been confirmed in human brains after ischemic stroke, with elevated levels of certain structural proteins in the tissue surrounding the infarct.¹⁹ The catch is that while the scar is initially protective, it eventually becomes an obstacle. Over the long term, the glial scar impedes the regrowth of nerve fibers (axons) trying to reconnect across the damaged zone, limiting functional recovery.²⁰ This dual role, protective in the short term and obstructive later, makes glial scarring one of the trickier problems in neurorehabilitation research.

How Parenchymal Scarring Is Detected

Detecting scarring depends on the organ involved. In the lungs, high-resolution CT scanning has become the primary diagnostic tool. It can provide a highly specific diagnosis of conditions like idiopathic pulmonary fibrosis in many patients without the need for a surgical biopsy.²¹ Patterns like honeycombing and ground-glass opacities on CT give clinicians a map of where scarring is active versus where it has already consolidated.

For kidneys, the imaging method of choice, especially in children, is a DMSA scan (a nuclear medicine scan using a radioactive tracer that binds to functioning kidney tissue). Areas of scarring show up as defects where the tracer is not absorbed. DMSA has become the standard for detecting both acute kidney infections and permanent cortical scars.²² The probability of abnormalities on DMSA scans increases with the severity of vesicoureteral reflux, making it a useful tool for stratifying risk in children with recurrent urinary tract infections.²³

Researchers are also working on blood and urine biomarkers that could detect scarring earlier or less invasively. In children with vesicoureteral reflux, urinary levels of certain proteins like NGAL show promise as markers for predicting renal scarring before it becomes visible on imaging.²⁴ Other urinary biomarkers tied to inflammation and fibrosis pathways, including TGF-β1 itself, are being studied as a way to monitor kidney injury without repeated scans.²⁵

Why Scarring Tends to Get Worse on Its Own

One of the more frustrating aspects of parenchymal scarring is that it can become self-perpetuating. Scar tissue is physically stiffer than normal tissue, and that stiffness itself activates more myofibroblasts, which lay down more collagen, which makes the tissue stiffer still. Researchers describe this as a mechanical feedback loop. In the lungs, for instance, the stiffened scar tissue promotes both myofibroblast contraction and further differentiation of normal cells into myofibroblasts.²⁶ The fibrosis can propagate even after the original trigger, whether that was an infection, a toxin, or an autoimmune flare, has been removed.²⁷

Detailed mapping of fibrotic tissue stiffness has shown just how dramatic these changes can be. Healthy organs have relatively uniform stiffness, but fibrotic tissues develop extreme spatial variation, with “peaks” of very stiff scar reaching up to 40 kilopascals right next to soft surrounding tissue as low as 0.5 kilopascals. These steep stiffness gradients appear to pull cells toward the scar, potentially expanding the fibrotic zone outward over time.²⁸ The self-reinforcing nature of this process helps explain why advanced fibrosis is so difficult to reverse and why early intervention, when the scarring is still limited, carries outsized importance.

Can Parenchymal Scarring Be Reversed

The short answer is: sometimes partially, rarely completely, and it depends enormously on the organ and the stage. The liver has the strongest track record for reversibility. In animal models, specialized immune cells called scar-associated macrophages can actively break down fibrotic collagen by producing enzymes that digest it. When these macrophages were depleted in experiments, the breakdown of liver scars slowed dramatically, confirming that the body has an active mechanism for clearing liver fibrosis.²⁹ In clinical practice, treating the underlying cause of liver disease, such as curing a hepatitis C infection or stopping alcohol use, can lead to measurable regression of fibrosis if the disease has not yet progressed to advanced cirrhosis.

Lung fibrosis is harder to undo. The two drugs currently approved for IPF, pirfenidone and nintedanib, slow the rate of lung function decline but do not reverse existing scarring. A systematic review of ten studies found that patients treated with either drug showed a reduced decline in lung capacity compared to placebo.³⁰ Both drugs appear to work in part by interfering with the TGF-β signaling pathway that drives myofibroblast activation.³¹ There is growing interest in whether these drugs could be useful against fibrosis in other organs as well, since the molecular pathways they target are not unique to the lungs.³²

Newer experimental approaches are also showing promise. In mouse models of lung fibrosis, antibodies targeting a signaling molecule called interleukin-11 not only prevented fibrosis from forming but also reversed established scarring, reducing both collagen deposition and the signaling pathways behind it.³³ These results are still in animal stages, but they represent a shift from simply slowing fibrosis to actually unwinding it.

Why Children Are Especially Vulnerable

Children face a unique version of the parenchymal scarring problem. Their organs are still growing and maturing, which means that scarring can interfere not just with current function but with the organ’s future development. In the kidneys, younger children are substantially more likely to develop new scars from vesicoureteral reflux. Data from the International Reflux Study found that children under two years old developed new scars at roughly twice the rate of those aged five and older.³⁴

Radiation therapy illustrates another dimension of this vulnerability. In adults, scarring from radiation depends primarily on the tissue’s capacity to repair itself. In children, radiation can impair or disable the organ’s maturational processes altogether, producing a spectrum of effects that simply does not exist in adults.³⁵ A scar in an adult kidney is a fixed loss of function. A scar in a toddler’s kidney may also limit how much that kidney can grow, compounding the functional deficit over a lifetime. This is one reason pediatricians monitor children with known renal scarring for blood pressure changes and kidney function well into adulthood.